📗 Cite This Artifact
Methylphenidate + iTBS for Apathy in AD (PRIME Trial)
Methylphenidate Primed iTBS for Apathy in Neurocognitive Disorders (PRIME)
Pathway Diagram
```mermaid
flowchart TD
AD["AD"]
style AD fill:#006494,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0
neurodegeneration["neurodegeneration"]
AD -->|"causes"| neurodegeneration
memory_loss["memory_loss"]
AD -->|"causes"| memory_loss
TAU["TAU"]
AD -->|"associated with"| TAU
IMMUNE_TOL["IMMUNE_TOL"]
AD -->|"causes"| IMMUNE_TOL
DEMENTIA["DEMENTIA"]
AD -->|"causes"| DEMENTIA
cholinergic_transmission["cholinergic_transmission"]
AD -.->|"inhibits"| cholinergic_transmission
PROTEOME["PROTEOME"]
AD -->|"regulates"| PROTEOME
CHOLINERGIC_TRANSMISSION["CHOLINERGIC_TRANSMISSION"]
AD -->|"associated with"| CHOLINERGIC_TRANSMISSION
TAU -->|"implicated in"| AD
TAU -->|"associated with"| AD
APOE["APOE"]
APOE -->|"associated with"| AD
BETA_AMYLOID["BETA_AMYLOID"]
BETA_AMYLOID -->|"causes"| AD
PHOSPHORYLATED_TAU["PHOSPHORYLATED_TAU"]
PHOSPHORYLATED_TAU -->|"causes"| AD
SOD1["SOD1"]
SOD1 -->|"associated with"| AD
TAU -->|"causes"| AD
AGE["AGE"]
AGE -->|"associated with"| AD
style neurodegeneration fill:#6d3000,stroke:#4fc3f7,color:#e0e0e0
style memory_loss fill:#6d3000,stroke:#4fc3f7,color:#e0e0e0
style TAU fill:#4a1a6b,stroke:#4fc3f7,color:#e0e0e0
style IMMUNE_TOL fill:#6d3000,stroke:#4fc3f7,color:#e0e0e0
style DEMENTIA fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
style cholinergic_transmission fill:#5d4400,stroke:#4fc3f7,color:#e0e0e0
style PROTEOME
Methylphenidate Primed iTBS for Apathy in Neurocognitive Disorders (PRIME)
Pathway Diagram
Overview
The PRIME Trial (NCT07279740) is a Phase 2 randomized clinical trial evaluating the combined use of intermittent theta burst stimulation (iTBS) and methylphenidate (MPH) for treating apathy in patients with Alzheimer's disease or mixed AD/vascular dementia. This novel combination approach targets apathy through both pharmacological dopaminergic enhancement and neuromodulatory brain stimulation mechanisms[@combined].
Trial Details
| Attribute | Details |
|-----------|---------|
| NCT Number | NCT07279740 |
| Phase | Phase 2 |
| Status | Recruiting |
| Sponsor | Sunnybrook Health Sciences Centre |
| Collaborators | Alzheimer's Society of Canada, Sunnybrook Research Institute, Brain Canada |
| Enrollment | 12 participants |
| Start Date | January 2026 |
| Primary Completion | October 2027 |
| Location | Toronto, Ontario, Canada |
| Principal Investigator | Krista Lanctot, PhD |
Apathy in Alzheimer's Disease: Clinical Significance
Prevalence and Impact
Apathy affects approximately 40-50% of AD patients, representing one of the most common neuropsychiatric symptoms. Unlike depression, which may co-occur but is distinct, apathy is characterized by:
- Reduced goal-directed behavior: Diminished initiative and activity
- Emotional blunting: Flat affect, lack of interest
- Cognitive passivity: Reduced engagement with окружающими
Apathy significantly impacts:
| Domain | Impact |
|--------|--------|
| Functional decline | Accelerated loss of daily living abilities |
| Caregiver burden | Increased caregiving demands |
| Quality of life | Reduced patient and caregiver wellbeing |
| Treatment outcomes | Reduced adherence to therapies |
Neurobiology of Apathy in dementia
Current evidence suggests apathy involves dysfunction in dopaminergic prefrontal circuits:
- Prefrontal cortex: Reduced activation during motivated tasks
- Anterior cingulate: Hypometabolism correlates with apathy severity
- Striatal dopamine: Reduced reward pathway activation
Apathy in dementia correlates with dopaminergic dysfunction in prefrontal-striatal circuits, distinct from depression which involves different neurocircuits[@apathy2021].
Detailed Study Visit Schedule
Screening Visit (Visit 1)
- Informed consent process
- Medical history review
- Physical examination
- Cognitive assessment (MMSE)
- Psychiatric evaluation
- Safety screening (ECG, labs)
- MRI (if recent not available)
Baseline Visit (Visit 2)
- Randomization
- Baseline assessments
- NPI-A completion
- Caregiver interview
- Safety checks
- First dose administration
Treatment Phase (Visits 3-6)
- Week 1: Daily treatment + assessments
- Week 2: Daily treatment + assessments
- Primary endpoint assessment
- Safety monitoring
Follow-up Visit (Visit 7)
- 4-week follow-up
- Secondary endpoint assessment
- Final safety evaluation
- Caregiver burden assessment
Clinical Trial Infrastructure
Good Clinical Practice (GCP) Compliance
This trial adheres to:
Data Safety Monitoring Board (DSMB)
A DSMB provides independent oversight:
Adverse Event Reporting
Frequently Reported Adverse Events
| Event | Expected Frequency | Management |
|-------|---------------------|-------------|
| Headache | 10-20% | Acetaminophen, adjust stimulation |
|Insomnia | 5-15% | Timing adjustment |
| Appetite decrease | 5-10% | Monitor, nutritional consult |
| Anxiety | 5-10% | Reassurance, dose adjustment |
| Nausea | 3-8% | Take with food |
| BP changes | 3-5% | Monitoring, intervention |
Serious Adverse Events (SAEs)
SAEs are reported within 24 hours:
- Unscheduled hospitalizations
- Life-threatening events
- Events causing significant disability
- Deaths (regardless of relationship)
Regulatory Pathway
FDA Engagement
This trial may inform future regulatory submissions:
European Medicines Agency (EMA)
For European sites:
Intellectual Property
The trial supports:
Study Design
Mechanism
This is a single-blind (outcomes assessor masked), parallel-group Phase 2 trial comparing:
- Experimental Arm: Methylphenidate + iTBS
- Control Arm: iTBS only (no medication for apathy)
The trial uses a novel combination approach:
Rationale for Combination
The combination approach is based on evidence that:
Competitive Landscape Analysis
Market Context for Apathy Treatment
The lack of approved apathy treatments represents a significant unmet need:
- Prevalence: 30-50% of AD patients have clinically significant apathy
- Impact: Estimated $12,000/year in additional care costs per apathetic patient
- Treatment Gap: No FDA-approved medications specifically for apathy in dementia
- Opportunity: Large market for effective interventions
Competitive Intelligence
Existing Approaches and Their Limitations
| Approach | Pros | Cons | Status |
|----------|------|------|--------|
| Methylphenidate alone | Evidence exists | Moderate effect | Investigational |
| TMS alone | Non-invasive | Limited evidence | Investigational |
| AChE inhibitors | Approved | Not apathy-specific | Approved for cognition |
| SSRIs | Approved | Not recommended | Off-label |
| Behavioral | Safe | Resource intensive | Not drug development |
This Trial's Competitive Advantages
The PRIME trial has several unique selling points:
Commercial Considerations
If successful, this treatment could address a significant market:
- Target Population: 30-50% of 6+ million AD patients in US
- Estimated Market: $2-5 billion annually
- Pricing Considerations: Cost-effectiveness analysis planned
- Reimbursement: CPT codes exist for both components
Strategic Positioning
The results of this trial will inform:
Patient and Caregiver Perspectives
Understanding the Caregiver Experience
Apathy profoundly affects caregivers:
Shared Decision-Making
The trial incorporates patient-centered approaches:
Quality of Life Considerations
Beyond clinical endpoints, the trial measures:
Implementation Science
Scaling Considerations
If successful, implementation will require:
Health Equity
The trial addresses equity through:
Sustainability
Long-term implementation would require:
Neurobiological Framework
The Apathy Triangle Model
The apathy triangle model provides a framework for understanding motivation deficits in neurodegenerative diseases:
flowchart TD
A["Anterior Cingulate<br/>Cortex (ACC)"] -->|"initiating action"| B["Goal-Directed<br/>Behavior"]
C["Dorsolateral Prefrontal<br/>Cortex (DLPFC)"] -->|"planning"| B
D["Orbitofrontal<br/>Cortex"] -->|"reward evaluation"| B
E["Striatum"] -->|"motor execution"| B
F["Ventral Tegmental Area<br/>(Dopamine)"] -->|"motivation signal"| A
F -->|"motivation signal"| C
F -->|"motivation signal"| D
style A fill:#e1f5fe,stroke:#333
style B fill:#c8e6c9,stroke:#333
style C fill:#e1f5fe,stroke:#333
style D fill:#e1f5fe,stroke:#333
style E fill:#e1f5fe,stroke:#333
style F fill:#fff3e0,stroke:#333
Dopaminergic Pathways in Motivation
The mesocorticolimbic dopamine system governs motivation:
Methylphenidate enhances dopaminergic signaling by:
- Blocking dopamine reuptake at the transporter (DAT)
- Increasing extracellular dopamine concentrations
- Modulating signal-to-noise ratio in reward circuits
TMS-Induced Neuroplasticity
iTBS produces activity-dependent plasticity through:
The combination approach may produce:
- Pharmacological Priming: Enhanced neural excitability
- Activity-Dependent Plasticity: iTBS-induced LTP
- Synergistic Effects: Greater than either treatment alone
Theoretical Basis for Combination
The scientific rationale for combining methylphenidate with iTBS includes:
Mechanism of Action
Methylphenidate (MPH)
Methylphenidate is a dopamine reuptake inhibitor that increases extracellular dopamine in the prefrontal cortex and striatum. Apathy in dementia is hypothesized to involve dopaminergic dysfunction in prefrontal circuits governing motivation and reward[@strafella2003]. By enhancing dopaminergic signaling, methylphenidate may improve goal-directed behavior and reduce apathy symptoms[@methylphenidate2015].
The pharmacological profile of methylphenidate includes:
- Primary Mechanism: Blockade of the dopamine transporter (DAT), preventing reuptake of dopamine into presynaptic neurons
- Secondary Effects: Mild norepinephrine reuptake inhibition
- Onset of Action: 30-60 minutes after oral administration
- Duration: 3-4 hours for immediate-release formulations
- Brain Regions Affected: Prefrontal cortex, striatum, nucleus accumbens
Multiple clinical studies have evaluated methylphenidate for apathy in dementia:
Intermittent Theta Burst Stimulation (iTBS)
iTBS is a form of repetitive transcranial magnetic stimulation (rTMS) that delivers bursts of high-frequency stimulation. When applied to the left dorsolateral prefrontal cortex (DLPFC), iTBS can modulate neural activity in circuits involved in motivation and emotional regulation[@bock2019]. The combination with methylphenidate may produce synergistic effects by enhancing dopaminergic tone while simultaneously facilitating neural plasticity in target circuits[@theta2020].
Key features of iTBS include:
- Stimulation Pattern: 600 pulses delivered in 2-second trains repeated every 10 seconds
- Total Duration: 3 minutes (compared to 30-40 minutes for conventional rTMS)
- Mechanism: Induction of long-term potentiation (LTP)-like plasticity
- Target: Left DLPFC (BA46/9)
- Intensity: 80% of motor threshold
Evidence for TMS in neuropsychiatric symptoms of dementia:
Methylphenidate is a dopamine reuptake inhibitor that increases extracellular dopamine in the prefrontal cortex and striatum. The mechanism:
| Property | Effect |
|----------|--------|
| Target | DAT (dopamine transporter) |
| Result | Increased synaptic dopamine |
| Circuit | Prefrontal cortex, striatum |
Apathy in dementia involves dopaminergic dysfunction in prefrontal circuits governing motivation and reward. By enhancing dopaminergic signaling, methylphenidate may improve goal-directed behavior[@methylphenidate2015].
Intermittent Theta Burst Stimulation (iTBS)
iTBS is a form of repetitive TMS delivering bursts of high-frequency stimulation:
| Parameter | Value |
|-----------|-------|
| Protocol | 2s on, 8s off |
| Pulses | 600 pulses/session |
| Duration | ~3 minutes |
| Target | Left DLPFC |
When applied to the left DLPFC, iTBS modulates neural activity in circuits involved in motivation and emotional regulation[@theta2020].
Patient Population
Inclusion Criteria
- Diagnosis: Alzheimer's disease or mixed AD/vascular dementia
- MMSE score: 10-28 (inclusive)
- Apathy: Clinically significant apathy (NPI-A ≥4 or equivalent)
- Medication: Stable dose of psychotropic medication ≥4 weeks
- Care partner: Must spend ≥10 hours/week with participant
Exclusion Criteria
- Psychiatric: Major Depressive Episode, active psychosis
- Agitation: Clinically significant agitation, delusions, hallucinations
- Medications: Currently taking dopaminergic agents (other than methylphenidate)
- TMS contraindications: Pacemakers, metallic implants, epilepsy history
- CNS pathology: Abnormalities other than AD
Endpoints
Primary Endpoint
- Measure: Change in Neuropsychiatric Inventory-Apathy (NPI-A) score
- Time Frame: 2 weeks
- Scoring: NPI-A based on care-partner scores (0-12, higher = worse)
Secondary Endpoints
Detailed Statistical Analysis
Sample Size and Power Calculations
Given the exploratory Phase 2 nature of this trial:
- Planned Enrollment: 12 participants (6 per arm)
- Effect Size Target: Cohen's d = 0.80
- Statistical Power: 80% at α = 0.05 (two-sided)
- Analysis Population: Intent-to-treat (ITT)
The sample size of 12 represents a power calculation based on:
- Expected dropout rate: 10%
- Primary analysis: mixed-effects model with repeated measures
Primary Efficacy Analysis
The primary efficacy analysis will compare:
Model Specification:
Change from Baseline = Baseline NPI-A + Treatment + Visit + Treatment × Visit + Age + Baseline MMSE + (Subject random effect)
Secondary Analyses
Sensitivity Analyses
Neuroimaging Substudies
Rationale for Imaging in Apathy Trials
Neuroimaging provides objective measures of treatment effects:
Expected Neuroimaging Findings
Based on prior research, treatment response may be associated with:
Imaging Protocols
| Modality | Sequence | Timing |
|---------|----------|-------|
| T1 MPRAGE | 1mm iso | Baseline, Week 2 |
| Resting fMRI | BOLD, 3mm | Baseline, Week 2 |
| DTI | 2mm iso | Baseline only |
| FDG-PET | 60min uptake | Baseline, Week 2 |
Biomarker Studies
Blood-Based Biomarkers
The trial may include collection of blood samples for:
###CSF Biomarkers (Optional Substudy)
Cerebrospinal fluid collection may include:
Biomarker Analysis Plan
- Primary Analysis: Correlation with clinical response
- Secondary Analysis: Baseline predictors of response
- Exploratory: Mechanistic pathways
Comparison with Other Apathy Trials
Active Clinical Trials for Apathy in AD
| Trial | Agent | Phase | Status | Mechanism |
|-------|-------|-------|--------|-----------|
| PRIME (NCT07279740) | MPH+iTBS | Phase 2 | Recruiting | DAT inhibitor + TMS |
| ACCEL | Methylphenidate | Phase 3 | Completed | DAT inhibitor |
| STIR-AD | TMS | Phase 2 | Completed | Neuromodulation |
| APATHY | AChE inhibitors | Phase 4 | Ongoing | Cholinergic |
Historical Context: Methylphenidate Trials
Lessons Learned
- Patient Selection: More severe apathy may respond better
- Dosage: Optimal dose range 10-40mg daily
- Duration: Effects seen at 2-4 weeks
- Combination: May enhance with non-pharmacological approaches
Rationale for Combination Approach
| Endpoint | Measure |
|----------|---------|
| Cognitive function | MMSE change |
| Functional abilities | ADL scales |
| Quality of life | QoL-AD |
| Safety | Adverse events |
Clinical Implications
If Successful
A positive result would:
Apathy in Alzheimer's Disease: Clinical Context
Prevalence and Impact
Apathy affects approximately 30-50% of patients with Alzheimer's disease, making it one of the most common neuropsychiatric symptoms[@mann2002]. Unlike depression, which is characterized by feelings of sadness and guilt, apathy is defined by a reduction in goal-directed behavior without associated emotional distress[@pollak2010]. This distinction is critical because:
- Diagnostic Overlap: Apathy and depression share some features but require different therapeutic approaches
- Disease Progression: Apathy typically increases with disease severity
- Caregiver Burden: Apathy significantly impacts caregiver stress and well-being
- Functional Decline: Apathy contributes to faster functional decline in AD
Neurobiological Substrates
Apathy in AD involves dysfunction in multiple neural circuits:
Biomarkers and Outcome Measures
Primary Outcome: Neuropsychiatric Inventory-Apathy (NPI-A)
The NPI-A is a subscale of the Neuropsychiatric Inventory that assesses:
- Frequency: 1-4 (occasionally to very frequently)
- Severity: 1-3 (mild to marked)
- Total Score: 0-12 (higher = worse apathy)
- 0-2: No significant apathy
- 3-5: Borderline apathy
- 6-12: Clinically significant apathy
Secondary Outcome Measures
Safety and Tolerability Considerations
Methylphenidate Safety Profile
Common considerations include:
- Cardiovascular Monitoring: Blood pressure and heart rate
- Weight Tracking: Appetite changes
- Sleep Evaluation: Insomnia risk
- Psychotic Symptoms: Worsening paranoia or hallucinations
TMS Safety Profile
iTBS is generally well-tolerated with:
- Minimal Side Effects: Headaches reported in 10-20% of subjects
- Seizure Risk: Very low (<0.1%) with appropriate screening
- Device Contraindications: Pacemakers, metallic implants, epilepsy history
Historical Context and Prior Research
This trial builds on a foundation of prior research in apathy treatment:
Future Implications
If successful, this trial could establish:
Cross-Links
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Apathy in Neurodegeneration](/mechanisms/apathy-neurodegeneration)
- [Transcranial Magnetic Stimulation](/therapeutics/transcranial-magnetic-stimulation)
- [Methylphenidate](/therapeutics/methylphenidate)
- [Dopamine](/proteins/d1-dopamine-receptor)
- [Dorsolateral Prefrontal Cortex](/brain-regions/dorsolateral-prefrontal-cortex)
- [Neuropsychiatric Symptoms in AD](/mechanisms/neuropsychiatric-symptoms-alzheimers)
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Dementia Treatment](/therapeutics/dementia-treatment)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
Mechanism Validation
This trial tests whether:
- Dopaminergic enhancement improves motivation
- Prefrontal stimulation modulates apathy circuits
- Combination produces synergistic effects
Related Pages
- [Alzheimer's Disease - Neuropsychiatric Symptoms](/diseases/alzheimer-disease)
- [Apathy in Neurodegeneration](/diseases/apathy-neurodegeneration)
- [Transcranial Magnetic Stimulation](/therapeutics/transcranial-magnetic-stimulation)
- [Dopamine Pathways](/mechanisms/dopamine-pathways)
Summary
The PRIME trial represents a novel therapeutic strategy combining dopaminergic pharmacotherapy with neuromodulation for apathy in AD. If successful, it would establish a new treatment paradigm for one of the most challenging neuropsychiatric symptoms in dementia.
Pathway Diagram
The following diagram shows the key molecular relationships involving Methylphenidate + iTBS for Apathy in AD (PRIME Trial) discovered through SciDEX knowledge graph analysis:
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | clinical-trials-methylphenidate-itbs-apathy-ad |
| kg_node_id | None |
| entity_type | clinical |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-4127f1b3849a |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-methylphenidate-itbs-apathy-ad'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-clinical-trials-methylphenidate-itbs-apathy-ad?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Methylphenidate + iTBS for Apathy in AD (PRIME Trial)](http://scidex.ai/artifact/wiki-clinical-trials-methylphenidate-itbs-apathy-ad)
http://scidex.ai/artifact/wiki-clinical-trials-methylphenidate-itbs-apathy-ad